Evolent Health (EVH) Cash from Financing Activities (2015 - 2026)

Evolent Health's Cash from Financing Activities history runs 12 years deep, the most recent figure standing at -$4.0 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 103.68% year-over-year to -$4.0 million; the TTM figure through Mar 2026 stood at -$147.8 million (down 259.89% YoY), while the FY2025 annual figure was -$35.9 million, down 6258.23% from the prior year.
• Cash from Financing Activities was -$4.0 million for Q1 2026 at Evolent Health, up from -$93.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $379.7 million in Q1 2023 to a low of -$103.4 million in Q2 2024.
• Historically, Cash from Financing Activities has averaged $21.9 million across 5 years, with a median of -$8.9 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 26901.72% in 2022, then tumbled 677.15% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at -$10.9 million in 2022, then sank by 677.15% to -$84.4 million in 2023, then jumped by 214.93% to $96.9 million in 2024, then plunged by 195.97% to -$93.0 million in 2025, then surged by 95.73% to -$4.0 million in 2026.
• The last three Cash from Financing Activities figures came in at -$4.0 million (Q1 2026), -$93.0 million (Q4 2025), and -$41.8 million (Q3 2025), per Business Quant data.